The stock of Intra-Cellular Therapies Inc (NASDAQ:ITCI) is a huge mover today! About 607,907 shares traded hands. Intra-Cellular Therapies Inc (NASDAQ:ITCI) has declined 48.80% since March 8, 2016 and is downtrending. It has underperformed by 58.11% the S&P500.
The move comes after 6 months negative chart setup for the $618.83 million company. It was reported on Oct, 11 by Barchart.com. We have $13.64 PT which if reached, will make NASDAQ:ITCI worth $30.94M less.
Analysts await Intra-Cellular Therapies Inc (NASDAQ:ITCI) to report earnings on November, 3. They expect $-0.81 EPS, up 10.99% or $0.10 from last year’s $-0.91 per share. After $-0.71 actual EPS reported by Intra-Cellular Therapies Inc for the previous quarter, Wall Street now forecasts 14.08% negative EPS growth.
Intra-Cellular Therapies Inc (NASDAQ:ITCI) Ratings Coverage
Out of 8 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 6 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 75% are positive. Intra-Cellular Therapies has been the topic of 15 analyst reports since August 6, 2015 according to StockzIntelligence Inc. As per Friday, November 6, the company rating was maintained by RBC Capital Markets. SunTrust downgraded the shares of ITCI in a report on Thursday, September 29 to “Neutral” rating. The firm has “Overweight” rating given on Thursday, June 2 by Piper Jaffray. As per Thursday, September 17, the company rating was maintained by Guggenheim. The rating was upgraded by Zacks on Friday, August 7 to “Sell”. The stock of Intra-Cellular Therapies Inc (NASDAQ:ITCI) has “Market Perform” rating given on Thursday, September 29 by JMP Securities. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, March 9 report.
According to Zacks Investment Research, “Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.”
Insitutional Activity: The institutional sentiment increased to 1.71 in 2016 Q2. Its up 0.25, from 1.46 in 2016Q1. The ratio improved, as 17 funds sold all Intra-Cellular Therapies Inc shares owned while 28 reduced positions. 23 funds bought stakes while 54 increased positions. They now own 30.01 million shares or 2.84% more from 29.18 million shares in 2016Q1.
Deutsche Bank & Trust Ag reported 10,399 shares or 0% of all its holdings. Weiss Multi has 0.14% invested in the company for 47,385 shares. Metropolitan Life Insurance Ny, a New York-based fund reported 25,164 shares. Macquarie Group Incorporated last reported 0% of its portfolio in the stock. American Grp last reported 0% of its portfolio in the stock. Ameriprise accumulated 0% or 8,460 shares. Columbus Circle has invested 0.21% of its portfolio in Intra-Cellular Therapies Inc (NASDAQ:ITCI). Vanguard Group has 2.36 million shares for 0.01% of their US portfolio. Nicholas Invest Prtnrs L P, a California-based fund reported 46,400 shares. Alpine Woods Invsts Limited Liability Company accumulated 0.12% or 53,144 shares. Credit Suisse Ag, a Switzerland-based fund reported 26,943 shares. Moreover, Nationwide Fund has 0% invested in Intra-Cellular Therapies Inc (NASDAQ:ITCI) for 22,497 shares. Blackrock Fund Advsrs accumulated 1.04M shares or 0.01% of the stock. Zurcher Kantonalbank (Zurich Cantonalbank) last reported 0% of its portfolio in the stock. Blackrock Invest Lc last reported 0.01% of its portfolio in the stock.
More notable recent Intra-Cellular Therapies Inc (NASDAQ:ITCI) news were published by: Fool.com which released: “Why Intra-Cellular Therapies Inc. Is Crashing Today” on September 29, 2016, also Marketwatch.com with their article: “Intra-Cellular Therapies shares plunge 68% after study results” published on September 28, 2016, Prnewswire.com published: “Intra-Cellular Therapies (ITCI) Alert: Shareholder Rights Law Firm Johnson …” on September 29, 2016. More interesting news about Intra-Cellular Therapies Inc (NASDAQ:ITCI) were released by: Fool.com and their article: “Why Intra-Cellular Therapies Inc Stock Jump 21.4% in April” published on May 07, 2016 as well as Wsj.com‘s news article titled: “Intra-Cellular Therapies Shares Plunge After Disappointing Drug Trial Results” with publication date: September 28, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.